Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
7.53
+0.11 (1.42%)
Apr 28, 2025, 9:38 AM EDT - Market open
Myriad Genetics Revenue
In the year 2024, Myriad Genetics had annual revenue of $837.60M with 11.21% growth. Myriad Genetics had revenue of $210.60M in the quarter ending December 31, 2024, with 7.12% growth.
Revenue (ttm)
$837.60M
Revenue Growth
+11.21%
P/S Ratio
0.80
Revenue / Employee
$310,222
Employees
2,700
Market Cap
693.59M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 837.60M | 84.40M | 11.21% |
| Dec 31, 2023 | 753.20M | 74.80M | 11.03% |
| Dec 31, 2022 | 678.40M | -12.20M | -1.77% |
| Dec 31, 2021 | 690.60M | 133.60M | 23.99% |
| Dec 31, 2020 | 557.00M | -81.60M | -12.78% |
| Jun 30, 2020 | Pro | Pro | Pro |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
MYGN News
- 2 days ago - Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting - GlobeNewsWire
- 6 days ago - Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing - GlobeNewsWire
- 19 days ago - Myriad Genetics Announces Inducement Awards - GlobeNewsWire
- 21 days ago - Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer - GlobeNewsWire
- 2 months ago - Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO - Benzinga
- 2 months ago - Myriad Genetics, Inc. (MYGN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth - GlobeNewsWire
- 2 months ago - Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio - GlobeNewsWire